The payment was triggered because Kura dosed the first AML patient in a Phase III trial of the menin inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback